BioLineRx (BLRX) Depreciation & Amortization (CF) (2014 - 2025)
BioLineRx's (BLRX) quarterly Depreciation & Amortization (CF) came in at $63000.0 in Q4 2025, down 96.6% year-on-year from $1.9 million in Q4 2024, and down 47.06% quarter-over-quarter from $119000.0 in Q3 2025.
BioLineRx (BLRX) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
BioLineRx's Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $63000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) fell 96.6% year-over-year to $63000.0 in Q4 2025; TTM through Dec 2025 was $523000.0, a 87.13% decrease from a year earlier, with the FY2025 full-year figure at $523000.0, down 87.13% from the prior year.
- Depreciation & Amortization (CF) eased to $63000.0 in Q4 2025 per BLRX's latest filing, from $119000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q4 2024 and bottomed at $63000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $181000.0 (2021), against an average of $366450.0.
- Across the five-year window, Depreciation & Amortization (CF) surged 280.09% in 2024 and plunged 96.6% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $174000.0 in 2021, then advanced by 7.47% to $187000.0 in 2022, then surged by 277.54% to $706000.0 in 2023, then surged by 162.32% to $1.9 million in 2024, then plunged by 96.6% to $63000.0 in 2025.
- Per Business Quant, the three latest BLRX Depreciation & Amortization (CF) figures stand at $63000.0 (Q4 2025), $119000.0 (Q3 2025), and $176000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | 63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 63,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Dec 31, 2024 | 1.85 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 840,000.00 |
| Sep 30, 2024 | 840,000.00 |
| Jun 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 476,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Dec 31, 2023 | 706,000.00 |
| Dec 31, 2023 | 706,000.00 |
| Sep 30, 2023 | 221,000.00 |
| Sep 30, 2023 | 221,000.00 |